CLOUDBREAK THERAPEUTICS

Cloudbreak Therapeutics is a clinical-stage biotechnology company focusing on ocular drug development. Cloudbreak Therapeutics operates a capital efficient business model based upon VIC + 505b(2). We repurpose approved systemic drugs for ocular delivery to treat eye diseases and quickly advance drug candidates to complete proof-of-concept (POC) Phase II clinical trials and to out-license global rights for Phase III clinical trials, product registration, and commercialization. Fully embracing the pharmaceutical development ecosystem, we utilize contract research organizations (CRO) for non-clinical, CMC and clinical development to efficiently maximize capital for drug development.

#SimilarOrganizations #People #Financial #Website #More

CLOUDBREAK THERAPEUTICS

Industry:

Biotechnology Health Care

Founded:

2015-09-01

Address:

Irvine, California, United States

Country:

United States

Website Url:

http://www.cloudbreaktherapeutics.com

Total Employee:

11+

Status:

Active

Total Funding:

171.22 M USD

Technology used in webpage:

Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Font Awesome Global Site Tag

Similar Organizations

lion-tcr-logo

Lion TCR

Lion TCR is a clinical-stage biotechnology company.

rain-therapeutics-logo

Rain Therapeutics

Rain Therapeutics is a operator of a clinical stage biotechnology company.

Current Employees Featured

jinsong-ni_image

Jinsong Ni
Jinsong Ni Founder, Chief Executive Officer, Chief Scientific Officer @ Cloudbreak Therapeutics
Founder, Chief Executive Officer, Chief Scientific Officer

van-dinh_image

Van Dinh
Van Dinh Co-founder, Chief Operating Officer @ Cloudbreak Therapeutics
Co-founder, Chief Operating Officer

Founder

jinsong-ni_image

Jinsong Ni

van-dinh_image

Van Dinh

Investors List

efung-capital_image

Official Site Inspections

http://www.cloudbreaktherapeutics.com

Host Informations
Whois Informations

Loading ...